NPCR CLINICAL EDIT CHECKS

Similar documents
Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer

ACRIN 6666 Screening Breast US Follow-up Assessment Form

Q&A. Collecting Cancer Data: Breast. Collecting Cancer Data: Breast 4/7/2011. NAACCR Webinar Series 1. Agenda

BRCA1 and BRCA2 Mutations

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

Field Epidemiology Training Program

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

2016 CWA Political Action Fund Administrative Procedures Checklist

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

US Public Health Service Clinical Practice Guidelines for PrEP

University College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

Daily Balancing in Maestro

Lyme Disease Surveillance in North Carolina

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) =

2017 CMS Web Interface

2017 CMS Web Interface

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Cardiac Rehabilitation Services

Swindon Joint Strategic Needs Assessment Bulletin

Obesity/Morbid Obesity/BMI

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

(Please text me on once you have submitted your request online and the cell number you used)

Osteoporosis Fast Facts

Fee Schedule - Home Health Care- 2015

Seeking and Appraising Evidence

FTD RESEARCH: The Value of Studies and Opportunities for Involvement

XX Abraxane 100 MG SUSR (CELGENE CORP)


2019 Canada Winter Games Team NT Female Hockey Selection Camp August 16-19, 2018

Medical Student Immunization Requirements

Making Medicare + Medi-Cal Work for California s Dual Eligibles

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

Reliability and Validity Plan 2017

Childhood Immunization Status (NQF 0038)

Session78-P.doc College Adjustment And Sense Of Belonging Of First-Year Students: A Comparison Of Learning Community And Traditional Students

TRANSPLANTATION AND CLINICAL IMMUNOLOGY. Proceedings of the Twenty-Second International Course, Lyon, May 1990

2018 CMS Web Interface

How to become an AME Online

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Volume Measurement at CT

WHAT IS HEAD AND NECK CANCER FACT SHEET

Completing the NPA online Patient Safety Incident Report form: 2016

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

SECTION O. MEDICATIONS

Paediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead

Folotyn (pralatrexate)

Background 1. Definition Fibroadenoma: Group of hyperplastic breast lobules composed of stromal and epithelial elements

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Agency Address Verification Monitoring Report - BENO

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Related Policies None

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10

Before Your Visit: Mohs Skin Cancer Surgery

Extended G/L Segment Codes

insights2017 QLD Kids Helpline Statistical Summary Queensland Insights into young people in Australia

PROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.

SUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

2018 CMS Web Interface

TO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:

Coding. Training Guide

CLINICAL MEDICAL POLICY

AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?

Imaging tests allow the cancer care team to check for cancer and other problems inside the body.

Sandostatin LAR (octreotide suspension) Document Number: IC-0111

2018 CMS Web Interface

The data refer to persons aged between 15 and 54.

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA

Reference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57

XX Abraxane 100 MG SUSR (CELGENE CORP

2018 CMS Web Interface

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Immunisation and Disease Prevention Policy

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Nutritional Intervention Effectiveness in Oncology Patients Receiving Active Anti-Cancer Treatment: A Systematic Review

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092

Perjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

MGPR Training Courses Guide

Code of Conduct for Employees

The Cannabis Act and Regulations

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit

Community Health Worker / Certified Recovery Specialist Training Application

Introduction to Exercise Physiology HKIN 206 Human Kinetics Program. Course Outline

Transcription:

NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff

PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t evaluate reprted prgnstic and treatment items fr cancer cases with specific tumr characteristics. Missing/Incmplete Tumr Characteristics (site/type/stage) Missing/Incmplete Site-Specific Factrs (prgnstic factrs) Missing/Incmplete First Curse Treatment Clinical Checks are based n cnsensus measures fr quality f cancer care develped by CC and NPCR fr specified cancers. Endrsed by Natinal Quality Frum, CC, ASCO, and NCCN. If the reprted treatment des nt appear t be cnsistent with widely recgnized standards f care r cases fail t cntain knwn prgnstic characteristics, a warning is generated. 2

PLUS 3

NPCR AUDIT INCLUDED CLINICAL CHECKS NPCR Clinical Check Edits 2010 Data Ttal Eligible Cases Ttal Cases With Warning Messages Ttal Cases Withut Warning Messages Percentage f Cases Withut Warning Messages Prgnstic and Staging Inf, Breast (Clin2) Prgnstic and Staging Inf, Cln (Clin2) Radiatin With Breast-Cnserving Surg (Clin2) Radiatin With Rectal Cancer Surgery (Clin2) Surgically Treated Nn-metastatic Cln Canc (Clin2) Systemic Treatment With Breast Surgery (Clin2) 3,646 1,323 2,323 63.71% 960 590 370 38.54% 1,326 614 712 53.70% 115 115 0 0.00% 520 209 311 59.81% 1,048 621 427 40.74% Any discrepancy generated warning that standard treatment nt captured r recrded. 4

Clinical Edit Checks 2010 Cnslidated Data % f Cases Withut Warnings Prgnstic and Staging Inf, Breast 64% Prgnstic and Staging Inf, Cln 39% Radiatin With Breast-Cnserving Surgery 54% Radiatin With Rectal Cancer Surgery 0% Surgically Treated Nn-metastatic Cln Cancer 60% Systemic Treatment With Breast Surgery 41% 0% 20% 40% 60% 80% 100%

TIMELINE FOR CLINICAL EDIT CHECKS CC-apprved Cancer Prgrams have already instituted similar checks with CP3R yu are ahead f the curve NPCR still unsure when CDC plans t begin requiring them NPCR is already using them in audits/evaluatins as indicatr FCDS may intrduce trial Clinical Checks fr pilt test facilities S, these are n ur radar but nt yet required by NPCR/FCDS 6

Clinical Edit Check Examples - Breast

CLINICAL EDIT CHECK EXAMPLE #1 Prgnstic and Staging Inf, Breast The purpse f this particular clinical check is t ascertain that staging and prgnstic infrmatin is cmplete fr breast cases eligible fr the Clinical Checks. Selectin Criteria: Primary Site = C500-C506, C508-C509 Sex = 2 Histlgic Type ICD-O-3 = 8000-8576,8940-8950,8980-8981,9020 Behavir Cde ICD-O-3 = 3 Age at Diagnsis 018-120 CS Mets at DX = 00 RX Summ--Surgery Prim Site = 20-90 8

CLINICAL EDIT CHECK EXAMPLE #1 Data Items used fr this Clinical Edit Check: Sex CS Lymph Ndes Eval Date f Diagnsis CS Mets at DX Age at Diagnsis CS Site-Specific Factr 1 Primary Site CS Site-Specific Factr 2 Histlgic Type ICD-O-3 CS Site-Specific Factr 9 Behavir Cde ICD-O-3 CS Site-Specific Factr11 CS Tumr Size CS Site-Specific Factr13 Reginal Ndes Examined CS Site-Specific Factr14 Reginal Ndes Psitive RX Summ--Surg Prim Site RX Summ Scpe Reg LN Sur 9

CLINICAL EDIT CHECK EXAMPLE #1 If any f the staging r prgnstic items is blank r unknwn (r nt dne), a WARNING is given t check fr the infrmatin. If CS Lymph Ndes Eval is 3-8 where Scpe f Reginal Lymph Nde Surgery is 0 (n reginal lymph ndes remved) and/r the Number f Reginal Lymph Ndes Examined is 00 (n ndes examined), a WARNING is given. Fr CS Lymph Ndes Eval f 3-8, reginal lymph ndes must have been micrscpically assessed. HER2 Test Interpretatin Fields (SSF 9, 11, 13, r 14) at least ne f the fur data items must nt be blank, 988, r 999 10

CLINICAL EDIT CHECK EXAMPLE #2 Radiatin With Breast-Cnserving Surgery The purpse f this particular clinical check is t ascertain that radiatin is given within ne year (365 days) f diagnsis and fully recrded fr nn-metastatic breast cancer treated with breast-cnserving surgery. Selectin Criteria: Primary Site = C500-C506, C508-C509 Sex = 2 Histlgic Type ICD-O-3 = 8000-8576,8940-8950,8980-8981,9020 Behavir Cde ICD-O-3 = 3 Age at Diagnsis 018-069 CS Mets at DX = 00 RX Summ--Surgery Prim Site = 20-24 11

CLINICAL EDIT CHECK EXAMPLE #2 Data Items used fr this Clinical Edit Check: Sex Date f Diagnsis Age at Diagnsis Primary Site Histlgic Type ICD-O-3 Behavir Cde ICD-O-3 CS Mets at DX RX Summ--Surg Prim Site Reasn fr N Radiatin Rad Reginal RX Mdality RX Date Radiatin RX Date Radiatin Flag RX Summ Surg/Rad Seq 12

CLINICAL EDIT CHECK EXAMPLE #2 If the Reasn fr N Radiatin is 2 r 5 (cntraindicated r patient died), n further editing is perfrmed by this edit. If the Reasn fr N Radiatin is 6 (planned, unknwn why nt given) r 8 (planned, unknwn if given), r RX Date--Radiatin Flag = 15 (planned), a WARNING is given: "Fllw this patient carefully fr recmmended radiatin." If the Reasn fr N Radiatin is 9 (unknwn whether radiatin recmmended r administered), a WARNING is given: "Patients fitting this prfile shuld usually receive radiatin - please check." 13

CLINICAL EDIT CHECK EXAMPLE #2 Fr all ther cases fitting the prfile, a check fr cmpletely cded radiatin fllws. Warnings are given under the fllwing cnditins: If Rad--Reginal RX Mdality is 00 (n radiatin) r 99 (unknwn) r blank - WARNING: "What is the Radiatin Mdality? Please check. If RX Date--Radiatin Flag is 10 (unknwn if radiatin administered), 11 (n radiatin administered) r 12 (radiatin administered, but date unknwn) - WARNING: "Please check fr the date Radiatin Therapy began. If RX Summ--Surg/Rad Seq is 0 (n radiatin and/r surgery, r unknwn if surgery and/r radiatin given) r 9 (sequence unknwn, but bth surgery and radiatin given) r blank - WARNING: "What is the Radiatin/Surgery Sequence? Please check." 14

CLINICAL EDIT CHECK EXAMPLE #2 Fr patients fitting the prfile, RX Date--Radiatin must n later than 365 days after Date f Diagnsis. If later than 365 days, a WARNING is given: "Patients fitting this prfile nrmally receive radiatin within 365 days." 15

CLINICAL EDIT CHECK EXAMPLE #3 Systemic Treatment With Breast Surgery The purpse f this particular clinical check is t verify that chemtherapy is fully cded fr patients with nn-metastatic large r nde-psitive, ER- and PR- resected breast cancer and that it is given within 120 days f diagnsis. This edit als verifies that hrmne therapy is fully cded fr these patients if ER and/r PR is psitive r brderline and that it is given within 365 days f diagnsis. 16

CLINICAL EDIT CHECK EXAMPLE #3 Selectin Criteria: Primary Site = C500-C506, C508-C509 Sex = 2 Histlgic Type ICD-O-3 = 8000-8576,8940-8950,8980-8981,9020 Behavir Cde ICD-O-3 = 3 Age at Diagnsis 018-120 CS Tumr Size = 011-989 CS Lymph Ndes = 130-800 CS Mets at DX = 00 CS Site Specific Factr 1 (Estrgen Receptr Assay) = 010-030 CS Site Specific Factr 2 (Prgesterne Receptr Assay) = 010-030 RX Summ--Surgery Prim Site = 20-90 17

CLINICAL EDIT CHECK EXAMPLE #3 Data Items Used in This Clinical Edit Check: Sex CS Lymph Ndes RX Summ Chem Date f Diagnsis CS Lymph Ndes Eval RX Date Chem Age at Diagnsis CS Mets at DX RX Date Chem Flag Primary Site CS Site-Specific Factr 1 RX Summ Hrmne Histlgic Type ICD-O-3 CS Site-Specific Factr 2 RX Date Hrmne Behavir Cde ICD-O-3 RX Summ--Surg Prim Site RX Date Hrmne Flag CS Tumr Size RX Summ Scpe Reg LN Sur RX Summ Systemic/Sug Seq Reginal Ndes Examined RX Date Systemic Flag Reginal Ndes Psitive 18

CLINICAL EDIT CHECK EXAMPLE #3 Only fr Ages 018-069: If CS Site Specific Factr 1 and CS Site Specific Factr 2 = 020 (negative/nrmal) r 030 (brderline): If RX Summ--Chem = 82, 85, r 87 (cntraindicated, patient died, r treatment refused), the case passes the edit, and n further editing dne. If RX Summ--Chem = 86 (planned, unknwn why nt given) r 88 (planned, nt yet started), a WARNING is given: Fllw this patient carefully fr recmmended chemtherapy., and n further editing dne. If RX Summ--Chem nt = 03 (chem, multiple agents), a WARNING is given: Patients with this prfile usually receive cmbinatin chemtherapy. Please check. If RX Date--Chem Flag = 10 (unknwn if chemtherapy administered), 11 (n chemtherapy administered), r 12 (chemtherapy administered but date is unknwn), a WARNING is given: Please check fr the date chem began RX Date--Chem must be n later than 120 days after Date f Diagnsis. 19

CLINICAL EDIT CHECK EXAMPLE #3 Ages 018-120: If CS Site Specific Factr 1 and/r CS Site Specific Factr 2 = 010 (psitive) r 030 (brderline): If RX Summ Hrmne = 82, 85, r 87 (cntraindicated, patient died, r treatment refused), the case passes the edit, and n further editing dne. If RX Summ Hrmne = 86 (planned, unknwn why nt given) r 88 (planned, nt yet started), a WARNING is given: Fllw this patient carefully fr recmmended hrmne tx., and n further editing dne. If RX Summ Hrmne nt = 01 (hrmne tx administered), a WARNING is given: Patients with this prfile usually receive hrmne therapy. Please check. If RX Date Hrmne Flag = 10 (unknwn if hrmne tx administered), 11 (n hrmne tx administered), r 12 (hrmne tx administered but date is unknwn), a WARNING is given: Please check fr date hrmne began. RX Date Hrmne must be n later than 365 days after Date f Diagnsis. 20

CLINICAL EDIT CHECK EXAMPLE #3 Ages 018-120: If RX Summ Chem is nt 82, 85, 86, 87, r RX Summ Hrmne is nt 82, 85, 86, 87, r 88: If RX Date Systemic Flag = 10 (unknwn if systemic therapy administered), 11 (n systemic therapy administered), r 12 (systemic therapy administered but date is unknwn), a WARNING is given: Please check fr date systemic therapy began. If RX Summ-Systemic/Sur Seq = 0 (n systemic therapy and/r surgery) r 9 (sequence unknwn) r blank, a WARNING is given: What is the SystemicSurgery Sequence? 21

FCDS EFFORTS TO IMPROVE RESULTS Educate Flrida Registrars n where t find key SSF data Educate Flrida Registrars n hw t cde key SSF fields Add key SSFs t DQI Reprt when missing, unknwn, nt dne Cmplete lp back t CC-apprved Cancer Prgrams frm medical nclgy practice reprting prgram nce fully n-line Wrk with natinal partners t enhance Clinical Edit Checks 22

QUESTIONS 23